ClinicalTrials.gg
RecruitingNCT07088302Updated Jan 16, 2026

Effect OF Lactase Enzyme Supplements ON Intolerance IN Preterm Neonates

An interventional study of lactase administration and placebo in Premature, Feeding Disorders and Lactase Deficiency, Congenital, sponsored by Alexandria University. Recruiting at 1 site in Egypt. Open to participants aged 3 Days to 1 Month. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
3 Days to 1 Month
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Premature Birth by Alexandria University — 5 open to participants now, 5 under way, none of them phase 3. Premature Birth · Alexandria University.

Planned enrollment
3rd of 10
120 · median 100
Started
2025
with 1 other
No phase
8 of 10
5 open now
Registered
9th of 10
by date

Among the 10 studies in Premature Birth by Alexandria University, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2025, is one of 8 with no phase, and was the 9th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

5 of the 10 studies in Premature Birth by Alexandria University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 3 Days to 1 Month · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Premature Birth by Alexandria University, or all of them as a file.
02

Study summary

This study aims to study the effect of lactase enzyme in preventing feeding intolerance in preterm neonates in neonatal intensive care unit at Alexandria University Children's Hospital.

03

Conditions studied

  • Premature
  • Feeding Disorders
  • Lactase Deficiency, Congenital
04

Who can participate

Ages eligible
3 Days to 1 Month
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria will be as follows:

  • Preterm neonates ≤ 32 weeks gestational age.
  • Start feeding in the first 72 hours of life. 8. Exclusion criteria

Patients with any of the following will be excluded:

  1. Parental consent lacking/refusal.
  2. Obvious major congenital abnormalities.
  3. Infants more than 72 hours of age at the time of randomization.
  4. Delayed introduction of feeding (beyond three days of life).
  5. Known galactosemia.
  6. Severe IUGR. -
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Lactase enzyme group

    Drug: lactase administration

  • Placebo comparator
    Control group

    Other: placebo

Interventions

  • Druglactase administration

    1 drop for each 10 ml of formula milk for 14 days

  • Otherplacebo

    10 ml milk without lactase

06

What researchers measure

Primary outcomes

  1. Feeding intolerance:

    vomiting number per day aspirates in ml/day abdominal distension by measuring abdominal circumference before and after feeds

    Time frame: first two weeks of life

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2026, 5 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 5 months is below that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2025
First posted
Jul 28, 2025
StartActual
Aug 30, 2025
Primary completionEst.
Feb 28, 2026
CompletionEst.
Mar 28, 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07088302
Responsible party
Marwa Mohamed Farag (Assistant professor of Pediatrics, Alexandria University) — Principal investigator
First posted
Jul 28, 2025
Start date
Aug 30, 2025
Primary completion
Feb 28, 2026 (estimated)
Completion
Mar 28, 2026 (estimated)
Last update
Jan 16, 2026

Study contacts

Marwa M Farag, PhD
Contact
d.marwa.farag@gmail.com
01288681788

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion